Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study - PubMed (original) (raw)
. 2004 Aug;17(8):895-904.
doi: 10.1038/modpathol.3800137.
Affiliations
- PMID: 15143334
- DOI: 10.1038/modpathol.3800137
Free article
Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study
Akishi Ooi et al. Mod Pathol. 2004 Aug.
Free article
Abstract
Overexpression of HER-2 and the epidermal growth factor receptor (EGFR) has been observed in many cancers, sometimes accompanied by gene amplification. To assess whether novel chemotherapies targeting these overexpressed proteins may be effective for the treatment of colorectal cancers, we examined the exact frequency of HER-2 and EGFR overexpression, the relationship between gene amplification and protein expression, and the heterogeneity of gene amplification within and between primary and metastatic tumors. We evaluated 244 colorectal cancers immunohistochemically. All tumors found to overexpress HER-2 or EGFR were further analyzed for gene amplification by fluorescent in situ DNA hybridization. Overexpression of HER-2 and EGFR was found in 8 (3%) and 19 (8%) of the 244 colorectal carcinomas, respectively. Gene amplification was observed in 100 and 58% of the tumors exhibiting HER-2 and EGFR overexpression, respectively. HER-2 amplification in cancer cells was characterized by clusters of hybridization signals, suggesting amplicons in homogeneously staining regions that were predominant in most primary and metastatic tumors. EGFR amplification, observed as scattered signals reminiscent of amplicons in double minute chromosomes, or coamplification of EGFR with the centromeric regions was observed as a minor population within primary tumors, and found in variety of populations in metastatic tumors. Overexpression of HER-2 and EGFR were observed in only a small fraction of colorectal carcinomas, but were frequently accompanied by gene amplification.
Similar articles
- EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.
Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B. Bhargava R, et al. Mod Pathol. 2005 Aug;18(8):1027-33. doi: 10.1038/modpathol.3800438. Mod Pathol. 2005. PMID: 15920544 - Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis.
Reis-Filho JS, Milanezi F, Carvalho S, Simpson PT, Steele D, Savage K, Lambros MB, Pereira EM, Nesland JM, Lakhani SR, Schmitt FC. Reis-Filho JS, et al. Breast Cancer Res. 2005;7(6):R1028-35. doi: 10.1186/bcr1341. Epub 2005 Oct 25. Breast Cancer Res. 2005. PMID: 16280056 Free PMC article. - Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate.
Wang X, Jones TD, Zhang S, Eble JN, Bostwick DG, Qian J, Lopez-Beltran A, Montironi R, Harris JJ, Cheng L. Wang X, et al. Mod Pathol. 2007 Feb;20(2):175-82. doi: 10.1038/modpathol.3800724. Epub 2006 Dec 22. Mod Pathol. 2007. PMID: 17192792 - Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers.
Marx AH, Burandt EC, Choschzick M, Simon R, Yekebas E, Kaifi JT, Mirlacher M, Atanackovic D, Bokemeyer C, Fiedler W, Terracciano L, Sauter G, Izbicki JR. Marx AH, et al. Hum Pathol. 2010 Nov;41(11):1577-85. doi: 10.1016/j.humpath.2010.02.018. Epub 2010 Jul 24. Hum Pathol. 2010. PMID: 20656317 - HER-2/neu overexpression is an independent prognostic factor in colorectal cancer.
Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Han WK, Kim H, Ryu SH, Sepulveda AR. Park DI, et al. Int J Colorectal Dis. 2007 May;22(5):491-7. doi: 10.1007/s00384-006-0192-8. Epub 2006 Sep 1. Int J Colorectal Dis. 2007. PMID: 16947041
Cited by
- Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics.
Tydings CW, Singh B, Smith AW, Ledwitch KV, Brown BP, Lovly CM, Walker AS, Meiler J. Tydings CW, et al. Protein Sci. 2024 Oct;33(10):e5141. doi: 10.1002/pro.5141. Protein Sci. 2024. PMID: 39275996 Free PMC article. Review. - Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival.
Leung PY, Chen W, Sari AN, Sitaram P, Wu PK, Tsai S, Park JI. Leung PY, et al. World J Gastroenterol. 2024 Feb 21;30(7):714-727. doi: 10.3748/wjg.v30.i7.714. World J Gastroenterol. 2024. PMID: 38515951 Free PMC article. - Extrachromosomal circular DNA in colorectal cancer: biogenesis, function and potential as therapeutic target.
Chen Y, Qiu Q, She J, Yu J. Chen Y, et al. Oncogene. 2023 Mar;42(13):941-951. doi: 10.1038/s41388-023-02640-7. Epub 2023 Mar 1. Oncogene. 2023. PMID: 36859558 Free PMC article. Review. - Prognostic and clinical significance of HER-2 low expression in early-stage gastric cancer.
Yang T, Xu R, You J, Li F, Yan B, Cheng JN. Yang T, et al. BMC Cancer. 2022 Nov 12;22(1):1168. doi: 10.1186/s12885-022-10262-7. BMC Cancer. 2022. PMID: 36371187 Free PMC article. - Genomic mapping of copy number variations influencing immune response in breast cancer.
López-Cade I, García-Barberán V, Cabañas Morafraile E, Díaz-Tejeiro C, Saiz-Ladera C, Sanvicente A, Pérez Segura P, Pandiella A, Győrffy B, Ocaña A. López-Cade I, et al. Front Oncol. 2022 Sep 1;12:975437. doi: 10.3389/fonc.2022.975437. eCollection 2022. Front Oncol. 2022. PMID: 36119512 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous